Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
12.18
+0.17 (1.42%)
At close: Aug 1, 2025, 4:00 PM
12.13
-0.05 (-0.41%)
After-hours: Aug 1, 2025, 4:10 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Revance Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $33, which forecasts a 170.94% increase in the stock price over the next year. The lowest target is $20 and the highest is $50.
Price Target: $33.00 (+170.94%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 30, 2025.
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +228.41% | Jun 30, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $21 → $20 | Buy | Maintains | $21 → $20 | +64.20% | May 15, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $21 | Buy | Reiterates | $21 | +72.41% | Apr 1, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $50 | Buy | Reiterates | $50 | +310.51% | Apr 1, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $22 → $26 | Strong Buy | Maintains | $22 → $26 | +113.46% | Mar 27, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
612.00K
EPS This Year
-2.79
from -5.15
EPS Next Year
-2.81
from -2.79
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | 3.2M | 35.7M |
| Avg | n/a | 612,000 | 18.5M |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | 5,733.3% |
| Avg | - | - | 2,915.0% |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.29 | -2.37 | -1.68 |
| Avg | -2.79 | -2.81 | -3.02 |
| Low | -3.30 | -3.27 | -4.27 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.